Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$164.66 - $218.08 $6,751 - $8,941
41 Added 2.71%
1,555 $262,000
Q2 2023

Aug 14, 2023

BUY
$176.32 - $240.22 $266,948 - $363,693
1,514 New
1,514 $328,000
Q2 2022

Aug 23, 2022

SELL
$93.97 - $143.33 $281 - $429
-3 Reduced 3.53%
82 $10,000
Q2 2022

Aug 16, 2022

BUY
$93.97 - $143.33 $7,047 - $10,749
75 Added 750.0%
85 $11,000
Q1 2022

May 16, 2022

BUY
$98.9 - $132.37 $98 - $132
1 Added 11.11%
10 $1,000
Q4 2021

Feb 14, 2022

BUY
$110.64 - $159.4 $110 - $159
1 Added 12.5%
9 $1,000
Q2 2021

Aug 16, 2021

BUY
$107.45 - $135.95 $322 - $407
3 Added 60.0%
8 $1,000
Q1 2021

May 17, 2021

BUY
$95.46 - $133.08 $477 - $665
5 New
5 $1,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.